Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy

Kidney Stones Clinical Trial

Official title:

Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After ESWL

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01560091
• Other study ID #: HN 4378
• Status: Withdrawn
• Phase: Phase 3
• First received: March 16, 2012
• Last updated: February 16, 2017
• Start date: March 2012
• Est. completion date: February 2013

Study information

• Verified date: February 2017
• Source: Albert Einstein Healthcare Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Tamsulosin is an alpha blocker usually prescribed for urinary complaints that has been shown to have some benefit in allowing kidney stones to pass through the ureter. Silodosin is a new alpha blocker that acts more rapidly than tamsulosin and has been shown to have specific receptors on the ureter. The investigators would like to see if there is some benefit to taking silodosin over tamsulosin after extra-corporeal shock wave lithotripsy (ESWL) to break kidney stones in terms of allowing the ureteral fragments to pass through the ureter. Our hypothesis is that silodosin will be at least as effective as tamsulosin in terms of allowing stones to pass, but may allow them to pass more quickly because of the rapid onset of action.

The side effect profile for both drugs is quite similar and tolerable. Patients may experience some common side effects associated with tamsulosin, including abnormal ejaculation, dizziness, rhinitis (runny nose, sneezing), and somnolence (sleepiness). Serious reactions include orthostatic hypotension, syncope (fainting), and priapism (prolonged undesired erection).

Patients may experience some common side effects with both silodosin and tamsulosin including ejaculatory dysfunction, dizziness, postural hypotension, diarrhea, and headache. Serious side effects are rare and include orthostatic hypotension, intra-operative floppy iris syndrome, syncope, and priapism.

Patients will experience the discomfort normally associated with kidney stones. All efforts will be made to alleviate these discomforts, including the use of the study medications. Patients will be able to take their routine prescribed pain medications, and will be asked to keep a record of their pain medication use.

The investigators will be randomly enrolling patients from all racial backgrounds and of both genders. They must have kidney stones ranging in size from 4mm to 1.0 cm and have no prior treatment for the study.

The primary endpoint of this study is the clearance rate of kidney stones. That is, in what period of time does the patient achieve clearance, is stone free and has all residual stones gone. The secondary endpoints of this study include analgesic use, residual stones remaining, need for re-treatment, need for intervention, steinstrasse clearance, and the need for hospitalization.

Description:

A comparison between two commonly used alpha blockers to determine if there is superiority in the secondary usage of aiding in stone passage

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Adults age 18 to 70

• Non-diabetics

• White blood cell count and serum creatinine level within normal range

• Urine analysis consistent with absence of infection

• Negative urine culture

• Absence of subjective or objective fever

• Ability to tolerate oral fluids and pain medication

• Unilateral ureteral calculus < 10mm visible on CT scan within the ureter

• Ability to make informed medical decisions regarding consent

• Willingness to follow up in the urology office

Exclusion criteria:

Adults unable to consent

• Individuals who are not yet adults (infants, children, teenagers)

• Pregnant women

• Prisoners

• Prior treatment for this particular stone

• Medical therapy only for stone disease

• Chronic narcotic use

• Current alpha blocker therapy

Related Conditions & MeSH terms

• Kidney Calculi
• Kidney Stones
• Nephrolithiasis

Intervention

Drug:
• silodosin
8mg PO Qday

Procedure:
• Extra-corporeal shock wave lithotripsy
ESWL

Drug:
• Tamsulosin
Tamsulosin 0.4mg PO Qday

Locations

Country	Name	City	State
United States	Albert Einstein Healthcare Network	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Albert Einstein Healthcare Network

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clearance rate of kidney stones (days)	The primary endpoint of this study is the clearance rate of kidney stones. That is, in what period of time does the patient achieve clearance, is stone free and has all residual stones gone. This outcome measure will be measured in days.	1 year
Secondary	Analgesic use	Analgesic use, number of pills of pain medication	1 year
Secondary	Residual stones remaining	Residual stones remaining, based on imaging	1 year
Secondary	need for re-treatment	need for re-treatment. Either the patient will need another ESWL, or hospitilization	1 year
Secondary	need for intervention	need for intervention. Either ESWL again or hospitilization and further procedures such as laser lithotripsy, percutaneous nephrolithotomy, open surgery	1 year
Secondary	steinstrasse clearance	steinstrasse clearance. Whether or not stone clearance is achieved or not	1 year
Secondary	need for hospitalization	need for hospitalization. either yes or no	1 year